Trial Profile

A Phase I, Open-label, Positron-Emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Savolitinib (Primary) ; Savolitinib (Primary)
Indications Colon cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cancer
Focus Pharmacokinetics
Sponsors AstraZeneca

Most Recent Events

30 Apr 2025 Results (n=7) assessing brain distribution and exposure of a microdose of carbon-11 labelled savolitinib using positron emission tomography (PET), in healthy adult volunteers under physiological conditions presented at the 116th Annual Meeting of the American Association for Cancer Research
11 Jul 2024 Status changed from recruiting to completed.
09 May 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com